Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cellegy Pharmaceuticals (CLGY) -- Ignore unavailable to you. Want to Upgrade?

To: Howard Hoffman who wrote (196)	9/17/1999 3:45:00 PM
From: Arthur Radley	Respond to of 322

Hadn't thought of that "angle".....(This is going to be a lot of fun, especially when you consider that the product takes care of a pain in the ass)...revenue should double just because of individuals buying the product to give to their "friends".(:>)

To: Howard Hoffman who wrote (196)	9/21/1999 1:40:00 PM
From: Arthur Radley	Respond to of 322

From theStreet.com today..... "Cellegy (CLGY:Nasdaq) was a dog for years. Worse, it works on diseases that no one likes to hear about. Seriously, investors pass on this company solely because of that. Try explaining that to the efficient market blowhards. Cellegy is working on a nitroglycerin gel, Anogesic, for anal fissures. The drug is finished with Phase III and the results should be out shortly. If they're positive, the drug could sell several hundred million annually, say people at two hedge funds that own this $90 million market cap company

To: Howard Hoffman who wrote (196)	10/5/1999 7:24:00 AM
From: Arthur Radley	Respond to of 322

We have news this morning. Also appears Phase III trials will conclude this month. Cellegy Awarded NIH Research Grant to Investigate New Treatments For Anorectal Disorders SOUTH SAN FRANCISCO, Calif., Oct. 5 /PRNewswire/ -- Cellegy Pharmaceuticals, Inc. (Nasdaq: CLGY - news) announced today it has received a $100,000 Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to investigate new treatments for anorectal disorders, including anal fissures and hemorrhoids. The SBIR grant will fund ongoing research efforts at Cellegy to advance the pharmacological understanding of anal disorders and strengthen Cellegy's proprietary position in the treatment of these conditions. Cellegy received the award based on a competitive review of the project's scientific and technical merit and potential for commercialization, as judged by two panels of prominent scientific researchers. ``This award of the SBIR grant is very good news for Cellegy. It will strengthen our Anogesic© ointment research and development program potentially adding other complimentary new products to treat various anal diseases,' commented John Dietrich, Ph.D., Cellegy's Vice President, Research and Development. ``If this initial research program is successful, we plan to apply for additional SBIR grant funding.' At the end of this month, Cellegy will complete testing on over 300 patients in a pivotal Phase III clinical trial of Anogesic ointment, a topical nitroglycerin ointment for the treatment of chronic anal fissures, a painful and debilitating condition. Each year in the United States alone there are some 235,000 new cases of anal fissures, approximately half of which require surgical intervention. In addition, about 1.3 million patients seek treatment each year from physicians for hemorrhoids, a related condition. However, some 9 million hemorrhoid sufferers do not visit their doctor because effective therapies do not currently exist. Cellegy Pharmaceuticals is engaged in the development of a new generation of prescription drugs and high performance cosmeceutical products based upon its patented topical and transdermal delivery technologies. In addition to Anogesic, Cellegy is developing a transdermal testosterone gel for the treatment of male hypogonadism, a condition that can result in decreased energy and libido in men generally over the age of 40. A pharmokinetic study using testosterone gel was recently completed and Cellegy plans to enter a Phase III clinical trial pending protocol approval by the U.S. Food and Drug Administration. Cellegy has also developed a line of high performance cosmeceutical products, which have been shown in clinical tests to produce significant improvements in the appearance of photodamaged and wrinkled skin. This press release contains forward-looking statements. Many factors could cause actual results to differ materially from those anticipated by the statements made in this press release. Among, but not limited to these, are unexpected clinical trial delays or regulatory difficulties relating to Anogesic, testosterone or other products and the outcomes of future research relating to this SBIR grant and products under development. SOURCE: Cellegy Pharmaceuticals, Inc.